FDA Takes Action to Make a Treatment Available for Autism Symptoms
On Sept. 22, 2025, the U.S. Food and Drug Administration (FDA) announced it had initiated the approval of…
-
-
GSK to invest $30 billion in R&D and Manufacturing in the U.S. over next 5 years
On Sept. 17, 2025, GSK announced plans to invest $30 billion across the United States in research and…
-
Emergent BioSolutions Receives New Contract for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
On Sept. 9, 2025, Emergent BioSolutions announced that a contract modification has been executed in the amount of…
-
Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88 Million
On Sept. 9, 2025, Elutia announced it has entered into a definitive agreement to sell its EluPro™ and…
-
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
On Sept. 4, 2025, Novavax announced a milestone payment from Takeda has been triggered by regulatory approval for Novavax’s…
-
Biotechnology | NIH | Vaccine
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS®, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
On Sept. 2, 2025, Emergent BioSolutions announced it had received a $30 million contract modification from the Biomedical Advanced…
-
Novavax’s Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
On Aug. 27, 2025, Novavax announced that the U.S. Food and Drug Administration (FDA) has approved the Nuvaxovid™ 2025-2026…
-
New Method Advances Reliability of Ai with Applications in Medical Diagnostics
On Aug. 20, 2025, two studies led by Johns Hopkins Kimmel Cancer Center, Ludwig Center, and Johns Hopkins Whiting School of…
-
Precigen Announces FDA Approval of PAPZIMEOS, the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
On Aug. 15, 2025, Precigen announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS™ (zopapogene imadenovec-drba)…
-
Biotechnology | Disease | FDA | Therapeutics
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B
On Jul. 31, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved Alhemo® (concizumab-mtci)…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Pharmaceutical | Therapeutics | Vaccine
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
On Jul. 22, 2025, AstraZeneca announces $50 billion of investment in the United States by 2030, building on…
-
Diagnostics | Disease | Energy | Environmental | EPA | Neurology | U.S. Congress
EPA eliminates research and development office, begins layoffs
On Jul. 18, 2025, The Environmental Protection Agency (EPA) said it is eliminating its research and development arm…
-
Supernus Pharmaceuticals to Acquire Sage Therapeutics for $795 Million
On Jun. 16, 2025, Supernus Pharmaceuticals and Sage Therapeutics announced a definitive agreement for Supernus to acquire Sage…
-
Biotechnology | Disease | Medical Device | Medicine | NIH | Therapeutics
‘Artificial pancreas’ transforming the lives of thousands of children and young people with type 1 diabetes
On Jun. 16, 2025, the National Institute for Health and Care Excellence (NICE) announced that the recommendation in…
-
Biotechnology | Clinical Research | COVID-19 | Infectious Disease | Influenza | Nanotechnology | Vaccine
Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses in Phase 3 Trial
On Jun. 11, 2025, Novavax announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent…
-
Artificial Intelligence | Biotechnology | Diagnostics | FDA | Medical Device | Pharmaceutical | Therapeutics | Vaccine | Women's Health
FDA Launches Agency-Wide AI Tool to Optimize Performance
On Jun. 2, 2025, the U.S. Food and Drug Administration (FDA) announces it has launched Elsa, a generative…
-
FDA approves Novavax COVID vaccine with new conditions
On May 17, 2025, The U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but placed additional conditions…
-
Gilead boosts planned U.S. investments by $11 billion amid tariff threat
On May 7, 2025, Gilead Sciences announced $11 billion in new planned investment in the U.S. to add…
-
Scientists Unveil the Structure of the Receptor Responsible for How We Taste Sweetness
On May 7, 2025, Howard Hughes Medical Institute Investigator Charles Zuker and members of his Columbia University lab…
-
FDA Advises Consumers, Tattoo Artists, and Retailers to Avoid Using or Selling Certain Sacred Tattoo Ink Products Contaminated with Microorganisms
On May 7, 2025, the U.S. Food and Drug Administration (FDA) alerted consumers, tattoo artists, and retailers of…
-
spinal tumour removed through a person’s eye socket for the first time
On May 6, 2025, in a first-of-its-kind surgery, a multidisciplinary team led by a University of Maryland Medical…
-
Agriculture | Biotechnology | Diagnostics | Disease | FDA | Veterinary
FDA approves gene-editing tech creating PRRS-resistant pigs
On Apr. 30, 2025, the U.S. Food and Drug Administration (FDA) approved the use of a gene-editing technology…
-
Agriculture | Artificial Intelligence | Biotechnology | COVID-19 | Diagnostics | Energy | Environmental | EPA | FDA | Forestry | Genomics | HIV | Infectious Disease | Influenza | Measles | Medicine | Nanotechnology | Neurology | NIH | Non-Profit Research | Oncology | Pharmaceutical | Polio | Stem Cell | Therapeutics | USDA | Vaccine | Veterinary | Women's Health
Cartoon Illustrating “The NIH and U.S. Healthcare in Crisis” Published
On Apr. 21, 2025, LifeScienceHistory.com published the cartoon: “The National Institutes of Health (NIH) and U.S. Healthcare in…
-
SHIELD-Utah Study Shows Novavax’s COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
On Apr. 15, 2025, Novavax announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and First…
-
Biotechnology | CDC | COVID-19 | Diagnostics | FDA | Infectious Disease | Influenza | Measles | Medicine | Neurology | NIH | Oncology | Organ Transplant | Pharmaceutical | Plague | Polio | Rare Disease | Stem Cell | Therapeutics | U.S. Congress | Vaccine | Women's Health
HHS starts layoffs of thousands of workers across its agencies
On Apr. 1, 2025, layoff notices began arriving for thousands of employees of the sprawling U.S. Department of…
-
Johns Hopkins and Family of Henrietta Lacks Break Ground on Building Named in Honor of Henrietta Lacks
On Oct. 28, 2024, the Johns Hopkins University and Johns Hopkins Medicine, together with descendants of Henrietta Lacks,…
-
Agriculture | Biotechnology | FDA | NIH | U.S. Congress
FDA Modernization Efforts for Establishing a Unified Human Foods Program launched
On Oct. 1, 2024, the U.S. Food and Drug Administration (FDA) announced that the unified Human Foods Program,…
-
Biotechnology | Diagnostics | FDA | Neurology | Therapeutics
FDA Approved Drug with New Mechanism of Action for Treatment of Schizophrenia
On Sept. 26, 2024, the U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squibb’s Cobenfy (xanomeline and trospium…
-
Biotechnology | COVID-19 | Diagnostics | NIH | Oncology | Therapeutics | Women's Health
New cancer diagnoses did not rebound as expected following pandemic
On Sept. 24, 2024, researchers at the National Institutes of Health (NIH) reported results of a study that…
-
Biotechnology | FDA | Influenza | Vaccine
FDA Approved Nasal Spray Influenza Vaccine for at home use
On Sept. 20, 2024, the U.S. Food and Drug Administration approved FluMist for self- or caregiver-administration. FluMist is…
